Veracyte Gets $28M In Series C For Molecular Diagnostics Products
South San Francisco-based molecular diagnostics firm Veracyte has raised $28M in a Series C funding. The firm said the funding included GE Ventures, as well as Domain Associates, Kleiner Perkins Caufield & Byers, TPG Biotech, and Versant Ventures. Veracyte is developing molecular cytology products, which are being applied to create a gene expression test to help reduce unnecessary surgeries as part of thyroid cancer diagnosis. The firm said the funding will go towards comercial expansion of its first product.
posted on Monday, July 1, 2013 (Link to more information)
Related companies:
Veracyte
Related stories:
> Veracyte Gets $45M In Financing
> Veracyte Files For IPO
> Veracyte Slips Slightly In IPO Debut
> Veracyte Gets $28M
> DiaCarta Gets $8M For Molecular Diagnostics
silicontap.com Home